Pliant Therapeutics Doses First Patient in FORTIFY Phase 1b Trial of PLN‑101095 for ICI‑Refractory Solid Tumors

Why This Milestone Matters

Pliant Therapeutics announced that the first patient has been dosed in FORTIFY, its Phase 1b indication expansion trial of PLN‑101095 for solid tumors that no longer respond to immune‑checkpoint inhibitors (ICI). This is the company’s first clinical move beyond its original autoimmune‑focused pipeline, highlighting a strategic shift toward oncology.

What Is PLN‑101095?

PLN‑101095 is a next‑generation, highly selective small‑molecule inhibitor of the cytokine interleukin‑17A (IL‑17A). By blocking this pathway, the drug aims to:

• Reduce tumor‑mediated immune suppression.
• Enhance the activity of existing immunotherapies.
• Provide a novel mechanism of action for patients who have progressed after ICI therapy.

Trial Design Overview

The FORTIFY study is a multi‑center, open‑label Phase 1b trial with the following key features:

1. Population: Adults with advanced solid tumors (including melanoma, non‑small cell lung cancer, renal cell carcinoma, and colorectal cancer) that are refractory to prior ICI treatment.
2. Dosing: Dose‑escalation followed by a cohort expansion at the recommended Phase 2 dose (RP2D).
3. Endpoints: Primary – safety and tolerability; Secondary – objective response rate (ORR), disease control rate (DCR), progression‑free survival (PFS), and pharmacokinetics.
4. Biomarker Strategy: Baseline and on‑treatment tumor biopsies to assess IL‑17A pathway inhibition and immune‑cell infiltration.

Key Takeaways for Investors and Clinicians

• First‑in‑class potential: If successful, PLN‑101095 could become the first IL‑17A inhibitor specifically validated for cancer immunotherapy.
• Strategic diversification: The trial expands Pliant’s addressable market beyond autoimmune diseases, potentially unlocking a multi‑billion‑dollar oncology opportunity.
• Risk mitigation: Early safety data will inform not only FORTIFY but also future combination studies with PD‑1/PD‑L1 blockers.

What’s Next?

Pliant plans to release initial safety data from the dose‑escalation portion in Q4 2024, followed by expansion‑cohort enrollment in early 2025. The company also hinted at parallel preclinical work exploring PLN‑101095 with CAR‑T cells and oncolytic viruses.

How This Affects Patients

For patients who have exhausted standard ICI options, FORTIFY offers a new therapeutic avenue that could re‑sensitize tumors to immunotherapy. The trial’s design includes comprehensive monitoring of immune responses, potentially paving the way for personalized combination regimens.

Conclusion

The dosing of the first patient in the FORTIFY trial marks a pivotal moment for Pliant Therapeutics, signalling its commitment to tackling ICI‑refractory cancers. Stakeholders should watch closely for safety readouts, which will shape the drug’s development trajectory and its role in the evolving landscape of cancer immunotherapy.